Fukatani Yusuke, Daizumoto Kei, Kadoriku Fumiya, Yamamoto Hiraku, Sasaki Yutaro, Ozaki Keisuke, Ueno Yoshiteru, Tuda Megumi, Kusuhara Yoshito, Fukawa Tomoya, Yamamoto Yasuyo, Yamaguchi Kunihisa, Takahashi Masayuki, Kanayama Hiroomi, Niki Mariko, Uehara Hisanori
The Department of Urology, Institute of Biomedical Sciences, Tokushima University Graduate School.
The Department of Dermatology, Institute of Biomedical Sciences, Tokushima University Graduate School.
Hinyokika Kiyo. 2022 Apr;68(4):107-111. doi: 10.14989/ActaUrolJap_68_4_107.
We report a case of papillary renal cell carcinoma that responded well to the combination of ipilimumab and nivolumab. The patient was a 68-year-old male who was being followed up for a small left renal mass without treatment. Two years later, computed tomography (CT) showed enlarged cervical and para-aortic lymph nodes, and lymph node biopsy suggested metastases of the cancer. After resection of the renal tumor, we performed pararenal aortic lymph node biopsy, and we diagnosed the case as papillary renal cell carcinoma type 1 with lymph node metastasis. The combination of ipilimumab and nivolumab each metastatic site showed regression on CT. Since immune-related adverse events occurred during the therapy nivolumab was discontinued, but partial response of the metastases was maintained.
我们报告一例对伊匹单抗和纳武单抗联合治疗反应良好的乳头状肾细胞癌病例。患者为一名68岁男性，因左肾小肿块接受随访，未进行治疗。两年后，计算机断层扫描（CT）显示颈部和主动脉旁淋巴结肿大，淋巴结活检提示癌症转移。在切除肾肿瘤后，我们进行了肾旁主动脉淋巴结活检，诊断该病例为1型乳头状肾细胞癌伴淋巴结转移。伊匹单抗和纳武单抗联合治疗后，每个转移部位在CT上均显示消退。由于治疗期间发生了免疫相关不良事件，纳武单抗停药，但转移灶仍维持部分缓解。
